tbuckley/cabot-search huggingface dataset:
Investigating associations between COVID-19 mortality and population-level health and socioeconomic indicators in the United States: A modeling study
Authors: Sasikiran Kandula, Jeffrey Shaman
Journal: PLoS Medicine (2021)

Background With the availability of multiple Coronavirus Disease 2019 (COVID-19) vaccines and the predicted shortages in supply for the near future, it is necessary to allocate vaccines in a manner that minimizes severe outcomes, particularly deaths. To date, vaccination strategies in the United States have focused on individual characteristics such as age and occupation. Here, we assess the utility of population-level health and socioeconomic indicators as additional criteria for geographical allocation of vaccines. Methods and findings County-level estimates of 14 indicators associated with COVID-19 mortality were extracted from public data sources. Effect estimates of the individual indicators were calculated with univariate models. Presence of spatial autocorrelation was established using Moran’s I statistic. Spatial simultaneous autoregressive (SAR) models that account for spatial autocorrelation in response and predictors were used to assess (i) the proportion of variance in county-level COVID-19 mortality that can explained by identified health/socioeconomic indicators (R 2 ); and (ii) effect estimates of each predictor. Adjusting for case rates, the selected indicators individually explain 24%–29% of the variability in mortality. Prevalence of chronic kidney disease and proportion of population residing in nursing homes have the highest R 2 . Mortality is estimated to increase by 43 per thousand residents (95% CI: 37–49; p &lt; 0.001) with a 1% increase in the prevalence of chronic kidney disease and by 39 deaths per thousand (95% CI: 34–44; p &lt; 0.001) with 1% increase in population living in nursing homes. SAR models using multiple health/socioeconomic indicators explain 43% of the variability in COVID-19 mortality in US counties, adjusting for case rates. R 2 was found to be not sensitive to the choice of SAR model form. Study limitations include the use of mortality rates that are not age standardized, a spatial adjacency matrix that does not capture human flows among counties, and insufficient accounting for interaction among predictors. Conclusions Significant spatial autocorrelation exists in COVID-19 mortality in the US, and population health/socioeconomic indicators account for a considerable variability in county-level mortality. In the context of vaccine rollout in the US and globally, national and subnational estimates of burden of disease could inform optimal geographical allocation of vaccines.
Abstract 2423: Discovery of ZN-e4, an irreversible EGFR-TKI with potent anti-tumor activity in EGFR mutant non-small-cell lung cancer
Authors: Jiali Li, Sunny Abraham, Jianhui Ma, Peter Q. Huang, Kevin D. Bunker, Fernando Doñate, Ahmed A. Samatar
Journal: Cancer Research (2021)

Abstract Small molecule tyrosine kinase inhibitors against the epidermal growth factor (EGFR) have made significant impact in the treatment of advanced non-small-cell lung cancer (NSCLC) with activating EGFR mutations. Although the first and second-generation EGFR inhibitors have remarkably improved survival in advanced EGFR mutant NSCLC patients, most of the patients develop acquired resistance. The gatekeeper mutation (T790M) is the most common acquired resistance mechanism to the first and second-generation EGFR inhibitors. To overcome the T790M acquired resistance, third-generation EGFR inhibitors, such as osimertinib, were developed. However, additional mutant selective EGFR inhibitors with improved toxicity profile are still needed as osimertinib treatment produced incidence of adverse events, such as diarrhea and skin rush. Here, we describe the identification and characterization of ZN-e4, an orally bioavailable, selective, irreversible third generation EGFR inhibitor. ZN-e4 selectively inhibited the kinase activity of several mutated forms of EGFR, including L858R, T790M/L858R, and Exon19 del in biochemical assay. In cell-based assays, ZN-e4 demonstrated a 20-40-fold selectivity ratio for mutant EGFR forms over the wild-type form thus minimizing the potential for on target toxicity. ZN-e4 potently inhibited the proliferation of NSCLC cell lines harboring EGFR activating and T790M mutation and induced tumor regression in small and large tumors with activating EGFR mutations in preclinical human NSCLC xenograft models. Taken together, our data suggest that ZN-e4 is a potent and selective third generation EGFR inhibitor. Currently, ZN-e4 is in a Phase I clinical trial in patients with EGFR mutant NSCLC showing clinical activity and encouraging toxicity profile. Citation Format: Jiali Li, Sunny Abraham, Jianhui Ma, Peter Q. Huang, Kevin D. Bunker, Fernando Doñate, Ahmed A. Samatar. Discovery of ZN-e4, an irreversible EGFR-TKI with potent anti-tumor activity in EGFR mutant non-small-cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2423.
Development of a targeted client communication intervention for pregnant and post-partum women: a descriptive study
Authors: Binyam Bogale, Kjersti Mørkrid, Brian O’Donnell, Buthaina Ghanem, Itimad Abu Ward, Khadija Abu Khader, Mervett Isbeih, Michael Frost, Mohammad Baniode, Taghreed Hijaz, Tamara Awwad, Yousef Rabah, J Frederik Frøen
Journal: The Lancet (2021)
Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids
Authors: Wenxiang Hu, Chunjie Jiang, Mindy Kim, Wenjian Yang, Kun Zhu, Dongyin Guan, Wenjian Lv, Yang Xiao, Jessica R. Wilson, Daniel J. Rader, Ching-Hon Pui, Mary V. Relling, Mitchell A. Lazar
Journal: Cell Metabolism (2021)
穏和減少した左室駆出率(EF)のHFに対して保持されたEFの心不全(HF)からのHFへの遅延性移行のためのカットオフ値としての55%左室駆出率(EF)
Authors: Ueda Tomoya, Kawakami Rika, Nishida Taku, Onoue Kenji, Soeda Tsunenari, Okayama Satoshi, Takeda Yukiji, Watanabe Makoto, Kawata Hiroyuki, Uemura Shiro, Saito Yoshihiko
Journal: Circulation (2015)
Abstract 1167: MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer
Authors: Tanya Ivanova Stoyanova
Journal: Cancer Research (2021)

Abstract Background: Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer that rarely develops de novo in primary tumors and is commonly acquired during the development of treatment resistance. NEPC is characterized by gain of neuroendocrine markers and androgen receptor (AR) loss, making it resistant to currently used therapeutic strategies targeting the AR signaling axis. Methods: We utilized whole proteomic analysis of a previously characterized NEPC model and identified MCM2, MCM3, MCM4, and MCM6 proteins as novel targets to inhibit NEPC growth. High levels of MCM2/3/4/6 were significantly enriched in human NEPC when compared to castration-resistant prostate adenocarcinoma in multiple datasets. Colony formation, 3D Matrigel drop and subcutaneous xenograft models of NEPC were used to test the effect of MCM2-7 inhibition using ciprofloxacin in NEPC. Results: Here, we report that MCM2, MCM3, MCM4, and MCM6 (MCM2/3/4/6) are elevated in human NEPC and high levels of MCM2/3/4/6 are associated with liver metastasis and poor survival in prostate cancer patients. MCM2/3/4/6 are four out of six proteins that form a core DNA helicase (MCM2-7) responsible for unwinding DNA forks during DNA replication. Inhibition of MCM2-7 helicase activity by treatment with ciprofloxacin inhibits NEPC cell proliferation and migration in vitro, significantly delays NEPC tumor xenograft growth, and partially reverses the neuroendocrine phenotype in vivo. Conclusions: Our findings uncover that MCM2/3/4/6 are markedly elevated in NEPC and represent new druggable targets for therapeutic intervention. The study further reveals that inhibition of MCM2/3/4/6 complex using ciprofloxacin or other targeted approaches may represent a new effective therapy for NEPC. Our studies warrant further exploration of design and screening for MCM2-7 complex-specific inhibitors. Citation Format: Tanya Ivanova Stoyanova. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1167.
Atherogenic Dyslipidemia on Admission Is Associated With Poorer Outcome in People With and Without Diabetes Hospitalized for COVID-19
Authors: Alfonso Bellia, Aikaterini Andreadi, Luca Giudice, Sofia De Taddeo, Alessio Maiorino, Ilenia D’Ippolito, Federica Maria Giorgino, Valeria Ruotolo, Maria Romano, Andrea Magrini, Nicola Di Daniele, Paola Rogliani, Davide Lauro
Journal: Diabetes Care (2021)

OBJECTIVE Identifying metabolic factors associated with critical disease can help to improve management of patients hospitalized for coronavirus disease 2019 (COVID-19). High triglycerides and low HDL levels characterize the atherogenic dyslipidemia closely related to insulin resistance and diabetes. We examined associations of atherogenic dyslipidemia detected on admission with outcome of COVID-19 during hospitalization. RESEARCH DESIGN AND METHODS We retrospectively analyzed clinical reports of 118 consecutive patients hospitalized for COVID-19 in Rome, Italy, between March and May 2020. Clinical characteristics, inflammation markers, and glucose and lipid metabolism parameters at admission were collected. Critical disease was defined as in-hospital death or need for endotracheal intubation. Associations were tested using logistic regression analysis. RESULTS Patients with critical COVID-19 (n = 43) were significantly older than those with noncritical disease (n = 75) and presented higher levels of fasting glucose, triglycerides, C-reactive protein, interleukin-6, procalcitonin, and d-dimer (P &amp;lt; 0.01 for all), whereas HDL levels were lower (P = 0.003). Atherogenic dyslipidemia was more frequent in patients with critical COVID-19 (46 vs. 24%, P = 0.011), as well as diabetes (37 vs. 19%, P = 0.026), and significantly associated with death or intubation (odds ratio 2.53 [95% CI 1.16–6.32], P = 0.018). Triglycerides were significantly associated with selected inflammatory biomarkers (P &amp;lt; 0.05 for all) and poorer outcome of COVID-19 during hospitalization in both the overall population and the subgroup with atherogenic dyslipidemia. CONCLUSIONS Atherogenic dyslipidemia detected on admission can be associated with critical in-hospital course of COVID-19. Further investigations are needed to elucidate the hypothetical role of insulin resistance and related lipid abnormalities in severe acute respiratory syndrome coronavirus 2 pathogenesis. Assessment of lipid profile should be encouraged in patients hospitalized for COVID-19.
Male reproductive function recovery after microsurgical varicocelectomy: Possible clinical and laboratory predictors
Authors: A.B. Shomarufov, V.A. Bozhedomov, F.A. Akilov, S.T. Mukhtarov, S.I. Giyasov, S.A. Abbosov, A.A. Kamalov
Journal: European Urology (2021)
Real life applicability of VI-RADS score for bladder cancer staging: Challenges of cut-offs definition and MRI sequences weighting
Authors: R. Clery, D. Bouda, A. Pachev, A. Santy, A. Goujon, S. Bebane, A. Giwerc, P. Meria, F. Gaudez, F. Meyer, J. Verine, P. Mongiat Artus, F. Desgrandchamps, E. De Kerviler, A. Masson Lecomte
Journal: European Urology (2021)
En-Bloc MoLEP (Moses Laser Enucleation of Prostate) vs. En-Bloc HoLEP: Comparing intra and post-operative outcomes for En-Bloc enucleation technique with early apical release, to treat patients affected by Benign Prostatic Enlargement (BPE)
Authors: M.E. Rodríguez Socarrás, J. Fernandez Del Alamo, J. Gomez Rivas, L. Llanes Gonzalez, D. Carrion, J. Reinoso Elbers, V. Cuadros Rivera, P. Juarez Del Dago, E. Garcia Cruz, F. Gomez Sancha
Journal: European Urology (2021)
SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data
Authors: Dung Nguyen, Peter Simmonds, Maurice Steenhuis, Elise Wouters, Daniel Desmecht, Mutien Garigliany, Marta Romano, Cyril Barbezange, Piet Maes, Bram Van Holm, Joaquín Mendoza, Salvador Oyonarte, Anders Fomsgaard, Ria Lassaunière, Eva Zusinaite, Katarina Resman Rus, Tatjana Avšič-Županc, Johan HJ Reimerink, Fiona Brouwer, Marieke Hoogerwerf, Chantal BEM Reusken, Gunnveig Grodeland, Sophie Le Cam, Pierre Gallian, Abdennour Amroun, Nadège Brisbarre, Christophe Martinaud, Isabelle Leparc Goffart, Hubert Schrezenmeier, Hendrik B Feys, C Ellen van der Schoot, Heli Harvala
Journal: Eurosurveillance (2021)

We compared the performance of SARS-CoV-2 neutralising antibody testing between 12 European laboratories involved in convalescent plasma trials. Raw titres differed almost 100-fold differences between laboratories when blind-testing 15 plasma samples. Calibration of titres in relation to the reference reagent and standard curve obtained by testing a dilution series reduced the inter-laboratory variability ca 10-fold. The harmonisation of neutralising antibody quantification is a vital step towards determining the protective and therapeutic levels of neutralising antibodies.
Abstract 2677: Clinicopathologic significance of CXCR2-CXCL1 signaling in cholangiocarcinoma
Authors: Yurie Yamamoto, Gen Tsujio, Tomohiro Sera, Atsushi Sugimoto, Syuhei Kushiyama, Sadaaki Nishimura, Kenji Kuroda, Ryota Tanaka, Kenjiro Kimura, Ryousuke Amano, Masaichi Ohira, Masakazu Yashiro
Journal: Cancer Research (2021)

Abstract Background: Cancer progression has been recognized as not only the proliferation of tumor cells but also an interaction between cancer cells and the surrounding stroma in the tumor microenvironment. Among the tumor stromal cells, cancer-associated fibroblasts (CAF) have been reported to be closely associated with tumor development in various solid carcinomas. We previously reported that chemokine (C-X-C motif) receptor 2 (CXCR2) signaling might play an important role for the pathogenic construction of CAF in the gastric cancer (GC) microenvironment, suggesting that GC cells might alter their adjacent stroma to form a permissive environment for tumor progression, and also we reported that chemokine (C-X-C motif) ligand 1 (CXCL1) from cells stimulated the recruitment of bone marrow cells into GC microenvironment via CXCR2 signaling, resulting in the malignant progression of GC. Following these findings, we reported that among the CXCR2 ligands, CXCL1 might play an important role in the malignant progression of GC via CXCR2 signaling. And then, some studies suggest that CXCR2-CXCL1 plays an important role in not only GC but also other solid cancer. However, there is no report about the clinicopathological significance of CXCR2-CXCL1 signal in cholangiocarcinoma. Then, we examined the clinicopathological significance of CXCR2-CXCL1 signal in cholangiocarcinoma in this study. Patients and Method: We retrospectively analyzed the total cases of 168 patients with cholangiocarcinoma. The expressions of CXCR2 and CXCL1 were investigated by immunohistochemistry, and we then analyzed the correlation between the clinicopathological features of 168 patients and the CXCR2 and CXCL1 expression level. Results: The CXCR2 and CXCL1 positive expression wad as follows: CXCR2 was 18.5% (31/168), CXCL1 was 72.8% (126/173), both CXCR2 and CXCL1 was 17.9% (30/168). Metastasis negative was correlated with CXCL1 expression. Low depth invasion was correlated with CXCR2 expression. The prognoses of the both CXCR2 and CXCL1 positive patients were significantly better than those of CXCR2 and/or CXCL1 negative patients (p&amp;lt;0.023, log rank). Conclusion:CXCLR2 and CXCL1 expression might be a better prognostic factor of patients with cholangiocarcinoma, and CXCR2-CXCL1 signaling might play an important role for tumor-suppressing effects of cholangiocarcinoma. Citation Format: Yurie Yamamoto, Gen Tsujio, Tomohiro Sera, Atsushi Sugimoto, Syuhei Kushiyama, Sadaaki Nishimura, Kenji Kuroda, Ryota Tanaka, Kenjiro Kimura, Ryousuke Amano, Masaichi Ohira, Masakazu Yashiro. Clinicopathologic significance of CXCR2-CXCL1 signaling in cholangiocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2677.
Abstract 2939: Activation of NRF2 signaling accelerates development of small cell lung cancer in mice
Authors: Samera Hamad, Stephanie Montgomery, Brittany Bowman, Ryan Murphy, Scott Randell, Trudy Oliver, D. Neil Hayes, M. Ben Major, Bernard Weissman
Journal: Cancer Research (2021)

Abstract Activating mutations in NRF2 frequently occur in human lung cancers, especially the E79Q mutation. However, how the activating mutation contributes to lung tumor development is not well understood. We used a new genetically engineered mouse model (GEMM), LSL-Nrf2E79Q/+ with Cre-inducible expression of this mutation within the endogenous Nrf2 locus, to understand its contribution to lung tumor development. We compared tumor development in p53fl/fl;p16fl/fl;LSL-Nrf2+/+ (WT) versus p53fl/fl;p16fl/fl;Nrf2E79Q/+ (Het) mice after intranasal instillation of Adenoviral Cre. While we did not observe a significant difference in lung adenocarcinoma (LUAC) between the Het and WT mice, the Het mice showed significantly higher frequencies of bronchial neuroendocrine tumors that resembled small cell lung carcinomas (SCLC) compared to WT. Additionally, the latency of SCLC lesions was lower in Het mice compared to WT. Surprisingly, LUACs in both groups were negative for NRF2 by IHC labeling despite recombination of the mutant Nrf2 allele. While all lesions in the WT and Het mice displayed positive ASCL1 and CGRp (NE markers) IHC labeling, only the SCLCs in Het mice expressed NRF2. This is the first study showing activation of Nrf2E79Q mutation drives development of small cell lung carcinomas. Interestingly, our data also suggest that the E79Q NRF2 activating mutation may inhibit the progression of LUAD. Citation Format: Samera Hamad, Stephanie Montgomery, Brittany Bowman, Ryan Murphy, Scott Randell, Trudy Oliver, D. Neil Hayes, M. Ben Major, Bernard Weissman. Activation of NRF2 signaling accelerates development of small cell lung cancer in mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2939.
Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma
Authors: E. Laukhtina, B. Pradere, D. D`andrea, G. Rosiello, S. Luzzago, A. Pecoraro, C. Palumbo, S. Knipper, P.I. Karakiewicz, V. Margulis, F. Quhal, R. Sari Motlagh, H. Mostafaei, K. Mori, V.M. Schuettfort, D. Enikeev, S.F. Shariat
Journal: European Urology (2021)
The Implications of Endoplasmic Reticulum Stress Response in the Prognosis and Pathogenesis of Myelodysplastic Syndrome
Authors: Ming-En Lin, Wen-Chien Chou, Yu-Chiao Chiu, Mei-Hsuan Tseng, Ming-Chih Liu, Chia-Wen Liu, Jih-Luh Tang, Ming Yao, Chi-Cheng Li, Shang-Yi Huang, Chien-Yuan Chen, Bor-Sheng Ko, Szu-Chun Hsu, Hsin-An Hou, Shang-Ju Wu, Chien-Ting Lin, Woei Tsai, Yidong Chen, Hwei-Fang Tien
Journal: Blood (2017)
Abstract 1041: Targeted inhibition of c-MET, Axl and DDR signaling pathways by merestinib enhances gemcitabine/<i>nab</i>-paclitaxel standard chemotherapy activity in pancreatic cancer models
Authors: Eda Shi, Margaret A. Schwarz, Md Sazzad Hassan, Urs von Holzen, Roderich E. Schwarz, Niranjan Awasthi
Journal: Cancer Research (2021)

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal malignancies in Western countries. Gemcitabine (Gem) plus nab-paclitaxel (NPT) is the standard chemotherapy treatment for PDAC leading to an average survival of 8.5 months. Activated signaling of c-MET, Axl and DDR1/2 pathways have been implicated in tumorigenic growth in many cancers including PDAC. Merestinib (Mer) is a potent, multikinase inhibitor that blocks c-MET, Axl and DDR1/2 pathways with IC50 values in the low nanomolar range. In this study, we investigated the antitumor potency of merestinib to enhance standard chemotherapy response in preclinical PDAC models. Methods: In vitro cell proliferation assays of PDAC-associated cells were evaluated by colorimetric WST-1 reagent. The mechanism of action was determined by Immunoblot analysis. Tumor growth studies were conducted in 6-week-old female NOD/SCID mice in subcutaneous xenografts. Results: In human PDAC AsPC-1 cell-derived subcutaneous xenografts, gemcitabine plus nab-paclitaxel and merestinib inhibited tumor growth while their combination had an additive effect. The net increase in tumor size was 357 mm3 in controls, 102 mm3 after Gem+NPT, 177 mm3 after Mer and 66 mm3 after Gem+NPT+Mer. Gemcitabine plus nab-paclitaxel and merestinib suppressed in vitro cell proliferation of PDAC epithelial cells and stromal cells. Importantly, the combination treatment demonstrated additive inhibitory effects. Inhibition in cell proliferation by Gem+NPT, Mer and Gem+NPT+Mer treatments was 54%, 14% and 82% (AsPC-1 cells, at medium dose levels), 54%, 4% and 73% (PANC-1 cells, at the highest dose level), 55%, 58% and 92% (PDAC-associated fibroblasts, at the medium dose level). Immunoblot analysis revealed that merestinib caused a decrease in the expression of phospho-c-MET, phospho-Axl, phospho-IGF-1R, phospho-AKT and an increase in apoptosis-related protein cleaved caspase-3 in PDAC cells either alone or in combination with gemcitabine plus nab-paclitaxel. Conclusion: Simultaneous inhibition of c-MET, Axl and DDR1/2 pathways by merestinib has antitumor efficacy in PDAC and it can significantly improve the standard chemotherapy response. This therapeutic approach might lead to a clinically relevant combination to increase PDAC patients' survival. Citation Format: Eda Shi, Margaret A. Schwarz, Md Sazzad Hassan, Urs von Holzen, Roderich E. Schwarz, Niranjan Awasthi. Targeted inhibition of c-MET, Axl and DDR signaling pathways by merestinib enhances gemcitabine/nab-paclitaxel standard chemotherapy activity in pancreatic cancer models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1041.
The risk of symptomatic postoperative lymphocele following pelvic lymph node dissection during robotic radical prostatectomy, does the type of energy matter? A single center analysis
Authors: A. Mellouki, F. Sartorio, I. Bentellis, Y. Ahallal, R. Haider, L. Mendel, A. Shaikh, D. Chevallier, M. Durand, B. Tibi
Journal: European Urology (2021)
Abstract 13014: High Density Lipoprotein Deliver and Regulate Microrna Expression in Endothelial Cells by Scavenger Receptor Class B Type 1
Authors: Zhijun Ou, Wei-Ping Dai, Hai-Yun Yuan, Hua-Ming Li, Yan Li, Xiang-Ming Zeng, Yu-Ming Peng, Xiao-Di Li, Jing-Song Ou
Journal: Circulation (2018)

Introduction: Previous studies showed that high density lipoprotein (HDL) can carry and deliver microRNAs into the cells. In the contrast, other studies demonstrated that HDL can not deliver microR...
Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity
Authors: Joel D. Pearson, Katherine Huang, Marek Pacal, Sean R. McCurdy, Suying Lu, Arthur Aubry, Tao Yu, Kristine M. Wadosky, Letian Zhang, Tao Wang, Alex Gregorieff, Mohammad Ahmad, Helen Dimaras, Ellen Langille, Susan P.C. Cole, Philippe P. Monnier, Benjamin H. Lok, Ming-Sound Tsao, Nagako Akeno, Daniel Schramek, Kathryn A. Wikenheiser-Brokamp, Erik S. Knudsen, Agnieszka K. Witkiewicz, Jeffrey L. Wrana, David W. Goodrich, Rod Bremner
Journal: Cancer Cell (2021)